February 19, 2026 update: A not yet recruiting trial examines whether Adapted Physical Activity affects the K Recovery Constant, a rate marker for muscle oxygenation recovery in menopausal depression.
What changed in the clinical trial listing?
The ClinicalTrials.gov entry for NCT07417709 now shows conditions including major depressive disorder and menopausal depression. It lists interventions as Adapted Physical Activity and CCATTP. The sponsor is Centre Hospitalier Universitaire de Besancon. The record indicates the trial status as not yet recruiting and directs readers to the official listing for updates. This update signals growing interest in non pharmacological approaches to depressive symptoms in menopausal populations and a push to measure how physical activity may influence muscle physiology endpoints.
Who is involved and what is being studied?
The target population is women experiencing menopausal depression and related depressive conditions such as major depressive disorder. The trial tests Adapted Physical Activity as an intervention and CCATTP as another listed intervention, with the aim of assessing effects on the K Recovery Constant, described as the rate of muscle oxygenation recovery. Sponsorship is provided by Centre Hospitalier Universitaire de Besancon. The study status remains not yet recruiting, which means no results are available yet. A link to the official ClinicalTrials.gov listing is provided for investigators and sponsors seeking regulatory information or updates.
What does the K Recovery Constant indicate about muscle oxygenation?
The K Recovery Constant is described as reflecting the rate at which muscle oxygenation recovers after exertion or stress. In this trial it is presented as a potential endpoint to quantify recovery dynamics in a menopausal population with depression. The current listing does not provide results; it only designates the measurement as part of the study design. Clinicians and regulatory professionals will watch how endpoints like the K Recovery Constant are defined, measured and validated as part of any future device or method used to assess muscle physiology in this context. Readers should note that the description comes from the trial listing and may evolve as the protocol is refined.
Official listing: ClinicalTrials.gov listing NCT07417709.
What regulatory considerations apply to this trial?
As a study described on ClinicalTrials.gov, the entry is subject to regulatory oversight applicable to clinical research. The page identifies a sponsor and multiple interventions and notes the status not yet recruiting. The description emphasizes an intended research purpose rather than a device claim. If a device is later introduced to measure the K Recovery Constant, regulatory labeling would address intended use, safety, performance, and evidence of efficacy in line with MDR Annex XIV guidance. The current text identifies the sponsor and location and references the official listing for ongoing regulatory updates. More information can be found at the official clinical trials listing.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07417709?term=medical+device
FAQ
- 1. What is being studied? The trial investigates Adapted Physical Activity and CCATTP as interventions and a K Recovery Constant as an endpoint in menopausal depression.
- 2. Who sponsors? Centre Hospitalier Universitaire de Besancon.
- 3. What does not yet recruiting mean? It means no results are available at present and participant enrollment has not started.
- 4. Where can I see the official listing? The listing is on ClinicalTrials.gov and linked in this article.
- 5. Is there a link to the official listing? Yes, the ClinicalTrials.gov page is provided in the article and within the body of this post.
Conclusion and implications for readers
At this stage the listing provides a framework for an approach that combines physical activity with a measurable muscle oxygenation endpoint in a menopausal depressed population. Regulators and researchers will monitor the protocol for defined safety measures, clear intended use if a device or method is introduced, and evidence to support any regulatory claims. For readers in clinical and regulatory roles, the main takeaway is that a non drug intervention is being studied with a defined physiological endpoint and sponsor oversight. The absence of results underscores the need for careful review of protocol details and future updates from the sponsor.
Disclaimer
This article is for professional use and reflects analysis based on the trial listing. It is not legal advice and should not replace regulatory consultation.
Announcement reference
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07417709?term=medical+device